How does the intracellular parasite causing leishmaniasis subvert its host cell’s membrane fusion mechanism? How does this subversion affect the functionality of infected cells and the immune response? To answer these questions, which are central to his research program, Professor Descoteaux will use cell biology, genetic, proteomic, and immunological approaches, as well as in vivo experimental models of leishmanisis.
“Leishmania is particularly adept at transforming macrophages into hospitable host cells and is a unique tool to study basic biological mechanisms of macrophages,” explains Professor Descoteaux.
There is yet no effective vaccine against the parasite Leishamia, which causes a spectrum of clinical symptoms ranging from skin sores to a visceral infection that can be fatal if not treated. Current treatments are costly and difficult to administer, and their efficacy is reduced by the spread of drug resistance. The scientific advances achieved by Professor Descoteaux’s team will help identify new therapeutic targets for infectious and inflammatory illnesses, including leishmaniasis, which is a serious health problem in nearly a hundred countries.
Professor Albert Descoteaux
received a doctorate in parasitology from McGill University before pursuing postdoctoral studies at the University of Kentucky and Harvard Medical School. For over twenty years, he has being developing unique expertise in the molecular and cellular biology of the Leishmania-macrophage interaction at Centre INRS–Institut Armand-Frappier and has received international scientific recognition in the field of parasitology. He held the Canada Research Chair in Infections and Immunity from 2001 to 2011 and is director of the doctoral program in immunology and virology
at INRS. ♦